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http://www.molecular-cancer.com/content/13/1/260RESEARCH Open AccessSMURF1 silencing diminishes a CD44-high cancer
stem cell-like population in head and neck
squamous cell carcinoma
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Background: Bone morphogenetic protein (BMP) signaling is thought to play key roles in regulating the survival
and maintenance of cancer stem cells (CSCs), which contribute to disease recurrences and treatment failures in
many malignances, including head and neck squamous cell carcinoma (HNSCC). Intracellular BMP signaling is
regulated by SMAD specific E3 ubiquitin protein ligase 1 (SMURF1) during cellular development. However, little is
known about the role or regulation of BMP signaling in HNSCC CSCs.
Methods: Two CSC-like populations, CD44high/BMI1high and CD44high/ALDHhigh, were enriched from HNSCC cell
lines and evaluated for the expression of SMURF1 by qRT-PCR, flow cytometry, and immunoblotting. The activation
status of BMP signaling in these populations was determined by using immunoblotting to detect phosphorylated
SMAD1/5/8 (pSMAD1/5/8) levels. Knockdown of SMURF1 transcripts by RNA interference was used to assess the role
of SMURF1 in BMP signaling and CSC maintenance. Loss of CSC-like phenotypes following SMURF1 knockdown was
determined by changes in CD44high levels, cellular differentiation, and reduction in colony formation.
Results: Populations of enriched CSC-like cells displayed decreased levels of pSMAD1/5/8 and BMP signaling target
gene ID1 while SMURF1, CD44, and BMI1 were highly expressed when compared to non-CSC populations. Stable
knockdown of SMURF1 expression in CSC-like cells increased pSMAD1/5/8 protein levels, indicating the reactivation
of BMP signaling pathways. Decreased expression of SMURF1 also promoted adipogenic differentiation and reduced
colony formation in a three-dimensional culture assay, indicating loss of tumorigenic capacity. The role of SMURF1
and inhibition of BMP signaling in maintaining a CSC-like population was confirmed by the loss of a CD44high
expressing subpopulation in SMURF1 knockdown cells.
Conclusions: Our findings suggest that inhibition of BMP signaling potentiates the long-term survival of HNSCC
CSCs, and that this inhibition is mediated by SMURF1. Targeting SMURF1 and restoring BMP signaling may offer a
new therapeutic approach to promote differentiation and reduction of CSC populations leading to reduced drug
resistance and disease recurrence.
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Head and neck squamous cell carcinoma (HNSCC) is
among the most prevalent cancers worldwide, with ap-
proximately 500,000 incidences per year, including close
to 40,000 new cases in the United States [1-3]. Despite the
successes of standard treatment modalities such as surgery,
radiation, and chemotherapies for the majority of patients
with early stage disease [4,5], patients with regional and
distant metastases or recurrent disease make up a substan-
tial proportion of the treatment failures [2,3,6], bringing
the 5-year survival rate to under 50%. Thus, the develop-
ment of chemoresistance and metastatic disease remains a
continuing challenge for HNSCC patients, and overcoming
these obstacles requires an improved understanding of the
underlying mechanisms contributing to tumorigenesis and
drug resistance.
Evidence suggests that a subpopulation of cells, known
as cancer stem cells (CSCs), possess the potential for
self-renewal, multipotent differentiation, and tumorigenesis
[5,7,8], and these cells may contribute to the aggression and
dismal prognosis of HNSCC. Although chemo- and radio-
therapy eliminate many of the bulk tumor cells, CSCs pos-
sess traits that allow them to survive and repopulate. The
surviving cells can then regenerate tumors leading to dis-
ease recurrences that are less responsive to conventional
therapies. In HNSCC, CSC populations were first identi-
fied using the cell surface marker CD44 [9]. A subset of
CD44high expressing cells was shown to possess stem cell
properties along with the ability to initiate tumorigenesis
in mice compared to CD44low/- cells [9-11]. Aldehyde de-
hydrogenase (ALDH) activity also has been used to iden-
tify CSCs in HNSCC [12-14]. ALDH activity correlates
strongly with increased resistance to chemo- and radio-
therapy [15,16], and the combination of ALDH activity
with CD44 expression is more selective for CSC-like pop-
ulations than either marker alone [17-20].
While it is established that the implantation of ex-
tremely small numbers of ALDHhigh/CD44high cells con-
sistently give rise to tumors in vivo further solidifying
their tumorigenic properties [19,21], it remains relatively
unclear how the expression of ALDH and CD44 are regu-
lated in these populations. For ALDH, the epithelial-to-
mesenchymal transition regulator Snail was found to be a
key factor in maintaining the CSC properties in HNSCC.
Knockdown of Snail decreased ALDH expression, inhib-
ited CSC-like properties, and attenuated tumorigenesis in
ALDHhigh/CD44high cells [12]. While factors regulating
CD44 expression in HNSCC are unknown, clues may
come from studies in chondrocytes where co-immunopre-
cipitation experiments identified the interaction of SMAD1
with CD44. The interaction of SMAD1 with CD44 pro-
vides a link between CD44 and the bone morphogenetic
(BMP) signaling cascade, which signals through a family
of SMAD proteins [22]. The SMAD1/CD44 interactionappears to sequester SMAD1 in the cytoplasm, but the
nuclear accumulation of SMAD1 increases upon BMP7
stimulation [23]. The SMAD1/CD44 interaction also is as-
sociated with reversible dormancy of CSCs along with the
potential for tumor recurrence and metastasis in prostate
cancer [24]. Thus, BMP signaling through SMAD proteins
may be important for regulating and maintaining HNSCC
CSCs and in the overall regulation of CD44 expression
and signaling.
BMPs are members of the transforming growth factor
beta (TGF-β) superfamily with diverse biological functions,
including regulation of embryogenesis, cell proliferation,
migration, differentiation, and apoptosis [25-28]. Extra-
cellular regulation of BMP signaling is tightly regulated
by factors such as noggin (NOG), chordin (CHRD), and
twisted gastrulation BMP signaling modulator 1 (TWSG1)
[29,30]. Intracellular regulation is primarily mediated by
SMAD-specific E3 ubiquitin ligase 1 (SMURF1) through
its interactions with SMADs. Recently, ubiquitin ligases
have emerged as critical regulators for the development
and function of stem cell and stem cell-like populations.
For example, the E3 ligases Itch and c-Cbl have been iden-
tified as regulators of hematopoietic stem cell homeostasis
and function [31,32]. In glioblastoma, two isoforms of the
protein Numb differentially interacted with the SCFFbw7
ubiquitin ligase assembly to regulate the glioblastoma can-
cer stem cell hierarchy [33]. Based on these findings, it is
likely that other E3 ligases play similar roles in other can-
cers. This prompted us to investigate the role of SMURF1
in the regulation of BMP signaling and in the maintenance
of HNSCC CSCs.
In this study, we investigated whether the E3 ligase
SMURF1 is involved in regulating BMP signaling and
the maintenance of CD44high cells in head and neck can-
cer cell lines. We demonstrated that cell lines grown
under non-adherent culture conditions or isolated from
ALDHhigh/CD44high populations showed inhibition of BMP
signaling. Silencing of SMURF1 expression increased BMP
signaling and reduced the abundance of the CD44high
population in HNSCC cell lines. The inverse relationship
between SMURF1 expression and BMP signaling indicates
that BMP signaling may be important in regulating CD44
expression and, in turn, regulating CSC populations in
HNSCC. Reducing SMURF1 activity to enhance BMP
signaling may limit CSC function in HNSCC and provide
new therapeutic approaches for reducing drug resistant
populations.
Results
Sphere cells generated from HNSCC cell lines show
CSC-like characteristics
To study the role of BMP signaling in modulating CSC
populations, we established stable sphere cultures to en-
rich for CSC-like cells from three HNSCC cell lines,
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chosen for their ability to form spheres, along with long-
term survival and sphere regeneration following multiple
passages in cell culture (Figure 1A). Sphere formation in
serum-free suspension cultures has been well established
as a means to enrich for cells with CSC-like properties,Figure 1 Sphere cells from HNSCC cell lines show CSC-like characteris
standard adherent growth conditions (top), as spheres in serum-free suspe
under adherent growth conditions in the presence of 10% FBS and 75 μg/mL
at 20x objective for monolayer and SDCs, 4x for sphere cultures. Scale bars re
and differentiation marker CD24 in sphere cells relative to monolayer cultures
gene as an internal control and shown as mean fold change ± SE (n≥ 3). (C)
showing the percentages of the CD44high populations in monolayer and sphe
Representative flow cytometry data showing the gating of the CD44high cells
for the indicated total number of independent experiments. Statistical analysi
n.s. = not significant (p > 0.05).including drug resistance, self-renewal capability, high
expression of stem cell markers (e.g., CD44, ALDH
and BMI1), tumor initiation, and differentiation cap-
acity [10,34-36].
To establish our system, we first sought to demon-
strate that sphere cells derived from the three cell linestics. (A) HNSCC cell lines grown as monolayers with 10% FBS under
nsion growth conditions (middle), and as sphere-derived cells (SDCs)
Matrigel (bottom). Images were taken using phase contrast microscopy
present 100 μm in length. (B) Expression of CSC markers CD44 and BMI1
by qRT-PCR. Expression was normalized to the GAPDH housekeeping
Summary of flow cytometry analysis of CD44 surface protein expression
re cells from TR146 (n = 8), SCC-58 (n = 8) and UMSCC-17B (n = 3).
are shown in Additional file 1: Figure S1. Data are presented as mean ± SE
s was performed using two-tailed Student’s t-test with equal variance.
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CSCs. To do this, we utilized single cell suspensions of
sphere cells or sphere cells that were able to re-establish
adherent monolayer cultures in the presence of Matrigel,
generating populations of sphere-derived cells or SDCs.
CSC-like cells grown as spheres in culture are highly
quiescent and divide slowly, limiting cell numbers and
analysis, so we used SDCs in some studies to partially
circumvent this issue. Sphere cells or SDCs grown for
18–24 hours on Matrigel showed increased expression
of CD44 and BMI1 (Figure 1B) along with an increase
in the percentage of cells in the CD44high population
(Figure 1C). BMI1 and CD44high are two reported markers
for HNSCC CSCs [9,37,38]. Representative flow cytometry
analysis of how the CD44high populations were measured
in each cell line is shown in supplementary Additional
file 1: Figure S1. CD24 expression, reported to be variable
in HNSCC CSCs [39], was upregulated in TR146 and
UMSCC-17B sphere cells (Figure 1B), but its expression
remained unchanged in SCC-58 sphere cells. Sphere cells
were highly resistant to cisplatin compared to their mo-
nolayer cultures (Additional file 2: Figure S2), and ALDH
activity was either unchanged or slightly reduced when
compared to those from cells grown as adherent mono-
layers (data not shown). Because CD44 and BMI1 expres-
sion were consistently expressed in sphere cells and SDCs
from the three cell lines, sphere cells grown under non-
adherent conditions for 10 to 14 days were used as repre-
sentative CSC-like populations, and all SDCs were derived
from these populations for the remaining studies.
BMP signaling and SMURF1 are differentially regulated in
sphere cells
To determine if BMP signaling pathways were differen-
tially regulated in sphere versus monolayer cells, we
compared the gene expression profiles of BMP signaling
molecules using qRT-PCR arrays. The BMP signaling
inhibitors SMURF1, BMPER, and BAMBI were upreg-
ulated in all sphere cell populations while the BMP
signaling target genes ID1 and ID2 were downregulated
(Figure 2A). However, BMPER and ID2 expression was
not consistent and varied between the three cell lines.
Because SMURF1 has been shown to inhibit mesenchymal
stem cell proliferation and differentiation [40] and to pro-
mote invasiveness and CSC properties in pancreatic can-
cer [41], we chose to validate its expression at the protein
level and determine if BMP signaling was inhibited in the
sphere cells. We confirmed that SMURF1 protein expres-
sion was increased in sphere cells grown in cell culture for
7 days when compared to SMURF1 levels in monolayer
cells, and that this increase persisted in sphere cells
through day 14 (Figure 2B). SMURF1 expression in mono-
layer cells was low or not detected. We then measured
phosphorylated SMAD1, 5 and 8 (pSMAD1/5/8) levels todetermine the status of BMP signaling in the sphere cells.
Phosphorylated SMAD1/5/8 proteins are indicative of
active BMP signaling; therefore decreased pSMAD1/5/8
levels indicate inhibition of this signaling pathway. Using
immunoblotting, we determined that the pSMAD1/5/8
levels in spheres were greatly reduced when compared to
those of cultured monolayer cells (Figure 2C), suggesting
that BMP signaling was inhibited in sphere cells but active
in monolayers. Reduced BMP signaling appeared to be
specific for the canonical BMP signaling pathway since
phosphorylated p38 MAPK levels, a downstream marker
of non-canonical BMP signaling, did not differ between
the sphere and monolayer cell populations (data not
shown).
Because the reduced levels of pSMAD1/5/8 could be
attributed to a loss or reduction of BMP receptor ligand
expression rather than inhibition of the pathway by
SMURF1, we measured BMP2, 4, and 7 expression by
qRT-PCR and secretion of BMP2 by ELISA (Additional
file 3: Figure S3). These BMPs activate the BMP signal-
ing pathway by increasing pSMAD1/5/8 phosphorylation
critical for cellular growth and differentiation [25,42,43].
The sphere cells showed increased expression of BMP2 and
BMP7 at the mRNA level (Additional file 3: Figure S3A),
and BMP2 levels in the supernatants from sphere cells were
higher than levels found in the cell culture supernatants
from the monolayer cells (Additional file 3: Figure S3B).
While levels of BMP2 production by the sphere cells
decreased over a 14-day period, BMP2 levels remained
higher, in general, than those found in the monolayer
cell culture supernatants. Taken together, our results indi-
cate that BMP signaling is reduced in sphere cells, and
that this process is regulated, at least in part, by SMURF1.
The insensitivity to the presence of BMP ligands provides
evidence for CSC-like maintenance through BMP sig-
naling inhibition, while increased BMP2 production
likely indicates a paracrine growth promoting function
of these cells.
BMP signaling is decreased in CD44high/ALDHhigh
populations
We next examined pSMAD1/5/8 levels in CD44high/
ALDHhigh cell populations to assess the activation status
of BMP signaling since CD44high/ALDHhigh cell popula-
tions have been shown to represent CSC-like populations
in HNSCC and are highly tumorigenic in vivo [14,20]. In
addition, confirmation of decreased pSMAD1/5/8 levels
in the CD44high/ALDHhigh cells would further support the
use of our sphere cell system to study the mechanism
behind SMURF1 regulation of BMP signaling in HNSCC
CSCs. TR146 and SCC-58 cells were cultured in standard
monolayer conditions and stained for ALDH activity
followed by CD44 cell surface immunostaining. Double
stained cells were sorted based on the CD44high/ALDHhigh
Figure 2 BMP signaling and SMURF1 are differentially regulated in HNSCC CSC-like sphere cells. (A) Summary of qRT-PCR array data
showing relative expression of BMP signaling inhibitors (SMURF1, BMPER, and BAMBI) and BMP signaling target genes ID1 and ID2 in sphere cell
cultures compared to the monolayer cell cultures. Data are shown as mean ± SE with n ≥ 3. (B) Immunoblotting of SMURF1 in monolayer cells
and spheres cells from 7-day and 14-day sphere cell culture, shown as a representative of at least three independent repeats. (C) Immunoblotting
of pSMAD1/5/8 and total SMAD1 in monolayer (Mo) and three independent, 14-day sphere cultures. β-actin was used as total protein loading
control for all samples.
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CD44high/ALDHhigh cells showed increased SMURF1 pro-
tein levels while pSMAD1/5/8 protein levels were reduced
compared to the CD44low/ALDHlow and CD44depleted/
ALDHlow (cells further depleted for CD44) populations
(Figure 3C and D). SMAD1 expression levels were
unchanged. These results suggest that BMP signaling
is regulated in a manner similar to that observed in the
sphere cell populations. We then asked if CD44high ex-
pression alone can serve as a marker for CSC-like cells in
our study by performing a correlation analysis between
CD44 and SMURF1. As expected, SMURF1 was highly
associated with CD44 surface expression (Figure 4A).
Flow cytometry analysis further indicated that SMURF1
expression was higher in CD44high than in CD44low cell
populations (Figure 4B and C), demonstrating that higher
SMURF1 levels are associated with cells reported topossess CSC-like properties. Based on these results,
we sought to further define the role of SMURF1 in regu-
lating BMP signaling.
SMURF1 knockdown reactivates BMP signaling in CSC-like
HNSCC cells
Our data suggested that SMURF1 plays a role in the
suppression of BMP signaling to maintain the CSC-like
population. Although extracellular inhibitors may con-
tribute to this inhibition, SMURF1 directly inhibits the
activation of SMAD1, 5, and 8 and blocks the down-
stream BMP signaling cascade [44,45]. To confirm this
finding, we performed an expression knockdown study
of SMURF1 using RNA interference. We transduced the
monolayer cultures with either SMURF1 shRNA lenti-
virus (shSMURF1) or non-targeting shRNA (shNeg) with
high efficiency (~90%) before placing the cells into cell
Figure 3 BMP signaling and SMURF1 are differentially regulated in CD44high/ALDHhigh sorted CSC-like populations. Representative FACS
analyses of sorted cells are shown in A and B. (A) ALDEFLUOR stained cells in the presence of ALDH activity inhibitor DEAB and double-stained
with APC-conjugated IgG isotype control. (B) Gating of CD44low/ALDHlow and CD44high/ALDHhigh populations. (C–D) Immunoblotting of SMURF1,
pSMAD1/5/8, and SMAD1 (as a control for total SMAD protein) in the sorted TR146 (C) and SCC-58 (D) cells shown as representatives of at least three
repeats from two independent cell sorting experiments. CD44+ cells in the CD44low/ALDHlow sorted population were magnetically captured and
removed to generate CD44depleted/ALDHlow cells. β-actin was used as a total protein loading control for all samples.
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different shRNA sequences were used to reduce SMURF1
expression, and the levels of SMURF1 mRNA were
determined by qRT-PCR (Figure 5A). One sequence
(shSMURF1-724) consistently reduced SMURF1 mRNA
levels to the greatest extent in all cell lines. Decreased
expression of SMURF1 was validated by immunoblotting
(Figure 5B) in SDCs grown in the presence of FBS and
Matrigel for 18–24 hours. Knockdown of SMURF1 led to
partial reactivation of the BMP signaling pathway, indi-
cated by the increase in pSMAD1/5/8 levels (Figure 5C).
Taken together, our results show that SMURF1 regulates
BMP signaling in CSC-like populations, which may have
implications in maintaining the CSC-like phenotype.
Inhibition of SMURF1 expression diminishes a
subpopulation of CD44high cells
SMAD1 has been shown to interact directly with the
intracellular domain of CD44 [22,23,46], and the E3 ligase
activity of SMURF1 targets SMAD proteins for degrad-
ation [25,47,48]. Thus, SMURF1 provides a functional link
between CD44 and the BMP signaling cascade. Based on
the relative increase in expression of SMURF1 in CD44highpopulations coupled with a decrease in BMP signaling, we
hypothesized that SMURF1 plays a role in maintaining
CSC-like cells within CD44high cell populations. Therefore,
decreasing SMURF1 expression could potentially reduce
the levels of CSC-like cells through BMP activation and dif-
ferentiation. Knockdown of SMURF1 expression decreased
the percentage of CD44high cells in SDC cultures grown
for 4 – 11 days (Figure 6A and B), suggesting the loss of a
specific subpopulation of CSC-like cells. The decrease in
the CD44high cells for TR146 SDCs following SMURF1
knockdown was highly reproducible in multiple, indepen-
dent experiments (n = 5) but it was not statistically signi-
ficant compared to the shNeg knockdown (p = 0.138) or
the parental (p = 0.067) control cells (Figure 6C). This was
likely due to variation in the parental and shNeg SDC
CD44high population enrichment from different experi-
ments. Compared to the parental and shNeg controls,
SMURF1 knockdown significantly reduced the number of
CD44high cells in SCC-58 SDCs (p = 0.0092 compared to
shNeg, p = 0.037 compared to parental; n = 7) as shown
in Figure 6D. We also noted that the CD44high popula-
tion in the TR146 SDCs was less than the CD44high popu-
lation in the SCC-58 SDCs, demonstrating the potential
Figure 4 SMURF1 is associated with CD44 surface expression in sphere-derived cells (SDCs). (A) Flow cytometry analysis of SDCs showing
a positive correlation (qualitatively represented by the grey arrow) between CD44 cell surface and intracellular SMURF1 protein expression. Cells
were co-stained with fluorescently labeled anti-CD44 (APC) and anti-SMURF1 (Pacific Blue) and the total population is shown. Isotype staining
control is shown in B. (B) Gating strategy used to define the CD44high (top ~10%) and CD44low (lower ~10%) SDC populations. (C) Histograms of
SMURF1 expression in CD44low and CD44high populations based on the gates drawn in B. The data shown are representative of at least three
repeats for each cell line (TR146, left column; SCC-58, middle column; UMSCC-17B, right column).
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Figure 5 SMURF1 knockdown reactivates BMP signaling in SDCs. (A) SMURF1 knockdown screening by qRT-PCR in lentivirus transduced cells
expressing negative knockdown shRNA control (shNeg) or one of three different shRNA constructs (shSMURF1-173, −724, and −332) targeting
SMURF1 transcripts for silencing. Expression levels are relative to non-transduced parental control cells. Expression was normalized to the GAPDH
housekeeping gene and presented as mean ± SD. Screening was performed in monolayer cells in duplicate. (B) SMURF1 immunoblotting in SDCs
expressing shSMURF1-724 shRNA gene silencing construct relative to shNeg and parental controls from two cell lines. (C) Immunoblotting of
pSMAD1/5/8 in SDCs from two cell lines expressing shSMURF1-724 shRNA gene silencing construct relative to shNeg, parental, and monolayer
cells. β-actin was used for a gel loading control. Data shown are representative of at least three independent experiments.
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theless, knockdown of SMURF1 greatly reduced the
CD44high population in both cases. Co-staining of CD44
and SMURF1 in SDCs further verified that the reduction
of a CD44high population correlated with the decreased
expression of the SMURF1 protein (Additional file 4:
Figure S4).
Decreased expression of SMURF1 promotes
differentiation and reduces tumorigenic capacity
To confirm the loss of a CD44high CSC-like population
following SMURF1 knockdown, we tested whether these
cells can be induced to undergo differentiation. To showdifferentiation capability, enriched CSC-like cells were
cultured in adipogenesis differentiation medium for
seven days. Lipid droplets were apparent in shSMURF1
SDCs after seven days in differentiating medium, but
droplets were not present or not as prevalent in the paren-
tal and shNeg control SDCs or monolayer cells (Figure 7A).
Both the parental and shNeg control SDCs showed similar
background Oil Red O staining. Comparative analysis
showed a significantly higher level (TR146, p < 0.0001;
SCC-58, p < 0.009) of Oil Red O staining of lipid droplets
in shSMURF1 SDCs than the shNeg or the parental SDCs
(Figure 7B). These data suggest that sphere-enriched
CSC-like cells have a progenitor-like phenotype that can
Figure 6 (See legend on next page.)
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Figure 6 SMURF1 inhibition reduces a CD44high cell population in SDCs. Representative flow cytometry analysis of CD44high cells in monolayer
and in sphere-derived cells (SDCs) enriched from TR146 (A) and SCC-58 (B) sphere cultures are shown. A CD44high population is reduced in SMURF1-
knockdown (shSMURF1) compared to shNeg and parental control SDCs after culturing in complete medium for 4 – 11 days. (C) Summary of flow
cytometry analysis of CD44high TR146 SDCs shown in A (n = 5). (D) Summary of flow cytometry analysis of CD44high SCC-58 SDCs shown in B (n = 7).
Data in C and D are presented as mean ± SE for the indicated number of independent repeats. Statistical analysis was performed using two-tailed
Student’s t-test with equal variance. n.s. = not significant (p > 0.05).
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support the idea that SMURF1 plays a role in maintaining
a CSC-like state.
Finally, we tested the ability of the sphere cell popula-
tions to form colonies from single-cell suspension in
three-dimensional (3D), anchorage-independent medium
supplemented with 20% FBS. Clonogenicity in anchorage-
independent growth medium is a method used to examine
the tumor initiating capacity of cells. The control shNeg
sphere cells formed colonies within 21 days, but shSMURF1
cells did not form colonies or formed a significantly lower
number of colonies (TR146, p = 0.03; SCC-58, p = 0.0002;
UMSCC-17B, p = 0.0003) (Figure 7C and D). These results
indicate that shSMURF1 sphere cells may have lost their
capacity for anchorage-independent survival and self-
renewal, suggesting a loss in tumorigenic capacity.
Discussion
Subpopulations of tumor initiating cells from HNSCC
are currently defined by their high expression of
CD44 and BMI1 along with their high ALDH activity
[13,14,19,38,49,50]. In addition, CD44high/ALDHhigh
cells are highly tumorigenic and recapitulate heterogeneous
tumors in mice. While the epithelial-to-mesenchymal
transition regulator Snail was found to be key in main-
taining the CSC properties in HNSCC through its regu-
lation of ALDH expression [12], little else is known
about how these populations are modulated or main-
tained. Here, we expand this line of investigation by
utilizing CD44high expressing cells to represent CSC-like
subpopulations from HNSCC cell lines combined with
an analysis of the role of BMP signaling in regulating
their maintenance. To do this, we enriched CSC-like
cell populations, grown as non-adherent spheres, from
three HNSCC cell lines. The sphere cells possessed
CSC-like characteristics, including high expression of
HNSCC CSC markers, CD44 and BMI1, resistance to
the anti-cancer drug cisplatin, regeneration of spheres
in suspension over multiple passages (self-renewal), and
formation of visible colonies in three-dimensional culture
assays. Sphere cells also showed increased expression of
SMURF1 and inhibition of BMP signaling, indicating a
potential regulatory mechanism for CSCs. The inverse
relationship between SMURF1 and activation of the BMP
signaling pathway was further confirmed in ALDHhigh/
CD44high populations, validating the use of our sphere cellculture system to test the hypothesis that BMP signaling
regulates the fate of HNSCC CSCs.
BMP signaling is essential for cellular development,
including induction of proliferation and differentiation,
and has been shown to influence CSC populations in
other cancers. In support of our hypothesis, activation of
the BMP signaling cascade was shown to suppress CSC
populations and metastatic potential of breast cancer
[51], inhibit the tumorigenicity of CSCs in osteosar-
coma and renal cell carcinoma [52,53], and reverse
CSC-like traits in intestinal adenoma [54] and brain
tumor-initiating cells [55]. Furthermore, inhibition of
BMP signaling enhanced the CSC-like traits and meta-
static potential of breast cancer cells [56]. While these
studies confirm that the inhibition of BMP signaling plays
a role in maintaining progenitor cells in a CSC-like state,
contradictory reports show that activation by BMP2 en-
hances CSC-like populations in ovarian carcinoma [57],
and BMP4 stimulates an epithelial-to-mesenchymal and a
CSC-like phenotype in a squamous cell carcinoma cell line
of the tongue [37]. Thus, the BMP signaling mechanisms
utilized by various cancers to maintain their CSC popu-
lations may be tumor type specific. Alternatively, other
mechanisms may come into play, which override the regu-
latory factors that contribute to inhibition or activation of
BMP signaling. As a result, studies need to be undertaken
to further define the role of BMP signaling in maintaining
or regulating CSC-like cells.
To this end, we predicted that activation of the canon-
ical BMP signaling pathway would counteract CSC phe-
notypes by signaling CSCs to undergo differentiation,
resulting in the loss of self-renewal and the overall CSC
population. In support of this idea, we determined that
HNSCC sphere cells deactivate BMP signaling intracellu-
larly by upregulating SMURF1, leading to decreased levels
of pSMAD1/5/8 and ID1, the canonical BMP receptor
signal transducer [30,58,59] and BMP signaling target gene
[26,60], respectively. In both sphere cells and CD44high/
ALDHhigh sorted cells, pSMAD1/5/8 was decreased. Re-
duced levels of pSMAD1/5/8 and increased CD44high
expression correlated strongly with increases in SMURF1
protein levels, indicating SMURF1 associated suppression
of BMP signaling and maintenance of the CSC-like state.
Knocking down SMURF1 partially restored BMP signaling
and enhanced the induction of CSC-like cells to undergo
differentiation as shown using an adipogenesis assay. The
Figure 7 SMURF1 knockdown promotes differentiation in SDCs and decreased colony formation by sphere cells. (A) Adipogenesis
culture as a measure for cellular differentiation. SDCs were grown in normal growth medium (top) or adipogenesis differentiation medium
(bottom) for 7 days. Lipid droplet staining by Oil Red O was observed in SDCs with shSMURF1 knockdown grown in adipogenesis medium
compared to shNeg or parental controls. Representative Oil Red O staining images shown are from the TR146 cell line. (B) Quantitation of Oil Red
O staining in shNeg and shSMURF1 expressing SDCs cultured in adipogenesis medium from two representative cell lines. Data shown as mean ±
SD, performed in triplicate experiments with multiple replicate wells. (C) Representative images of colony formation by SDCs in Matrigel
anchorage-independent three-dimensional cultures supplemented with 20% FBS. (D) Summary of colony formation shown as mean number of
colonies ± SE per 2,500 cells plated performed with three different cell lines as independent biological replicates (TR146, n = 2; SCC-58, n = 3;
UMSCC-17B, n = 4). Statistical analysis was performed using two-tailed Student’s t-test with equal variance.
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type of the sphere-enriched cells. In addition, reactivation
of BMP signaling through suppression of SMURF1 reduced
clonogenicity of CSC-like cells as shown by their inability
to form colonies in anchorage-independent, 3D culture
supplemented with FBS. Because differentiation and loss
of clonogenicity occurred only after downregulation of
SMURF1 and reactivation of BMP pathway, these results
support our hypothesis that SMURF1 inhibition of BMP
signaling supports the maintenance of CSC-like tumor
population.
SMURF1 targets receptor-regulated SMAD proteins,
primarily SMAD1, 5 and 8, in the BMP signaling path-
way for degradation through association with inhibi-
tory SMAD6/7, or I-SMADs [43-45]. Through I-SMADs,
SMURF1 also can induce ubiquitination and degradation
of BMP type I receptors, inhibiting the BMP signaling cas-
cade [61]. While pSMAD1/5/8 levels were reduced overall
in the presence of increased expression of SMURF1 in our
studies, decreases in SMAD1 expression were not detec-
ted, a surprising result since SMURF1 targets SMADs for
degradation. It also is possible that partial degradation of
the targeted SMADs by SMURF1 may be occurring, and
changes were below the detection limit of our assays.
While other methods will need to be employed in order
address this possibility, our observations suggest that
regulation of BMP signaling by SMURF1 is likely to be
more complex than previously thought, and it may explain
why BMP signaling was only partially restored by reduced
expression of SMURF1 in our assays.
To add to this complexity, previous studies in chon-
drocytes have demonstrated a direct interaction between
CD44 and SMAD1 [22,23]. Here, CD44 acts as an intra-
cellular scaffold protein to localize SMAD1 near BMP
receptors, likely enhancing SMAD1 phosphorylation and
activation [23]. Binding to CD44 in CSC-like cells may
protect SMAD1 from degradation by SMURF1 but can
also sequester the protein from phosphorylation and acti-
vation. How SMAD1 association with CD44 is regulated
is not known. However, it is likely that the SMAD1/CD44
interaction provides a more precise and rapid response to
BMPs as well as extracellular matrix proteins and condi-
tions making the degradation of SMAD1 undesirable. It
also is possible that partial release of SMAD1 from CD44
may occur upon loss of SMURF1 or limited activation of
the BMP receptor. Thus, the role of SMAD1/CD44 signal-
ing in the context of HNSCC CSCs warrants further
investigation.
While our data are the first to implicate SMURF1 in
the regulation of a CSC-like population, SMURF1 may
play a similar role in other cancers. In human colorectal
cancer, elevated expression of SMURF1 has been shown
to correlate with cancer progression and prognosis [62].
In pancreatic cancer, SMURF1 amplification promotestumor invasiveness [41], suggesting that SMURF1 might
be used as an indicator of progression and/or prognosis
for some cancers including those of the head and neck.
While we have not yet undertaken such a study, the
expression levels of SMURF1 in primary, recurrent, and
drug resistant HNSCC tumors may be informative.
The recognition that other ubiquitin ligases play key
roles in regulating both stem cells and CSC populations
is becoming more widespread. The F-box protein Fbxw7,
which is the substrate-recognition subunit of an SCF-type
ubiquitin ligase complex, interacts with and mediates the
ubiquitylation of c-Myc [63]. The ubiquitin-dependent de-
gradation of c-Myc has been found to be essential for
maintenance of the quiescence and reconstitution capacity
of normal hematopoietic stem cells. For CSCs, Takeishi
et al. [64] showed that Fbxw7 plays a pivotal role in main-
tenance of quiescence in leukemia initiating cells (LICs) in
chronic myeloid leukemia by reducing the level of c-Myc.
Abrogation of quiescence in LICs by Fbxw7 ablation in-
creased LIC sensitivity to the tyrosine kinase inhibitor
imatinib, and the combination of Fbxw7 ablation with
imatinib treatment resulted in a greater depletion of LICs.
Furthermore, King et al. [65] demonstrated that mutations
in Fbxw7 specifically enhanced cancer-initiating cell activ-
ity in collaboration with Notch1 oncogenes in a model of
T-cell acute lymphoblastic leukemia but spared normal
hematopoietic stem cell function. Finally, the E3 ligase,
Skp2, has been shown to be overexpressed in numerous
human cancers and plays a critical role in cell-cycle pro-
gression, senescence, metabolism, cancer progression, and
metastasis. By using a Skp2 inhibitor, Chan et al. showed
Skp2 positively regulates CSC populations and self-renewal
ability [66]. Notably, the Skp2 inhibitor exhibited potent
antitumor activities in multiple animal models and coop-
erated with chemotherapeutic agents to reduce cancer cell
survival. Based on these and other studies, ubiquitin li-
gases are promising targets for restricting cancer stem cell
populations and cancer progression. In this regard, small
molecule compounds that block the WW1 domain of
Smurf1 from interacting with Smad1/5 have been repor-
ted in mouse cell lines [67], pointing to the feasibility of
targeting human SMURF1 for therapeutic intervention.
Conclusions
Our findings suggest that SMURF1 inhibition of BMP
signaling in CSC-like populations potentiates the long-
term survival and maintenance of CSCs in head and neck
cancer. Increased expression of SMURF1 and sup-
pressed BMP signaling were found in sphere cell cultures
and CD44high/ALDHhigh sorted populations. Restoration
of BMP signaling by silencing SMURF1 reactivated BMP
signaling, leading to increased cellular differentiation and
reduction in the CD44high CSC phenotype. Our data
strongly suggest a loss in self-renewal and tumorigenicity
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SMURF1 represents a potential drug target to inhibit the
maintenance and progression of CSCs.
Methods
Cell lines and cell culture conditions
The HNSCC cell lines TR146, SCC-58, and UMSCC-17B
were from the laboratory of Dr. Mark Herzberg, and their
sources of origin and culture conditions were described
previously [68]. Cells were cultured and maintained on
standard tissue-culture treated flasks in Dulbecco’s Modi-
fied Eagle Medium/Ham’s F-12 50:50 mix (DMEM/F-12)
supplemented with 10% fetal bovine serum (FBS) and
0.2% Primocin™ (InvivoGen, San Diego, CA, USA).
The cells were maintained in 5% CO2 at 37°C. Each
cell line was tested periodically for Mycoplasma expres-
sion by qPCR.
Sphere cell culture
Sphere cells were cultured as described previously but
with the following modifications [10,34,35]. Monolayer
cells were harvested by trypsinization when the flasks
were approximately 75% confluent and cultured in
DMEM/F-12 supplemented with 0.4% bovine serum al-
bumin or BSA, 10 ng/mL b-FGF, 20 ng/mL EGF, and
5 μg/mL insulin. Cells were cultured as single-cell sus-
pensions in ultralow attachment culture flasks (Corning
Inc., Corning, NY) for 10 to 14 days. Spheres were collected
every 3 – 4 days by gravity to remove dead and non-sphere
forming cells in the supernatant. The spheres were washed
with PBS, and separated into single cell suspensions by
incubating with 1 mL of 0.25% trypsin-EDTA for 2 – 4 min
at room temperature. To generate sphere-derived cells
(SDCs) for short-term proliferative growth studies, single
cell suspensions of sphere cells were cultured on adherent
tissue-culture treated flasks in complete medium supple-
mented with 75 μg/mL Matrigel™ Basement Membrane
Matrix Growth Factor Reduced (Stemcell Technologies
Inc., Vancouver, BC, Canada).
Cell sorting for CD44high/ALDHhigh cells
Monolayer cultured cells (15–20 ×106) were harvested at
approximately 70% confluency and stained for ALDH
activity using an ALDEFLUOR™ Kit (Stemcell Technolo-
gies Inc.) based on the manufacturer’s protocol. Follow-
ing ALDEFLUOR staining, cells were centrifuged and
resuspended in ice-cold staining buffer (ALDEFLUOR
buffer containing 2% FBS). Allophycocyanin (APC) con-
jugated rat monoclonal antibody against human CD44
(clone IM7; eBioscience Inc., San Diego, CA) was added
at a 1:100 dilution and incubated on ice for 30 min in
the dark. APC conjugated rat IgG2b isotype (eBioscience
Inc.) was used as a negative staining control. Cells were
washed with 10x volume of staining buffer and the cellnumber adjusted to 1 × 107 cells/mL with staining buffer
for sorting. Fluorescence activated cell sorting (FACS)
was performed using a BD FACSAria II (BD Biosciences,
San Jose, CA) equipped with a 100 μm nozzle. CD44high/
ALDHhigh cells were sorted for by gating from the top 10%
of double APC/FITC positive cells. CD44low/ALDHlow/-
cells were selected by gating for the lower 10 – 20% of the
APClow/FITClow/- cells. To further deplete CD44 positive
cells, the sorted cells were expanded under standard
monolayer culture conditions for four days, followed by
CD44-positive cell depletion using an EasySep APC selec-
tion kit (Stemcell Technologies Inc.). Cultured CD44low/
ALDHlow/- sorted cells were stained with APC conjugated
anti-CD44 antibody, washed and magnetically captured
and removed. Flow-through cell suspension was collected
through magnetic separation several times, generating a
population of CD44depleted/ALDHlow cells.
Gene expression analysis by qRT-PCR and PCR array
Gene expression analysis by real-time quantitative RT-PCR
(qRT-PCR) was performed using standard techniques.
Total RNA extraction from cultured cells was performed
using an RNeasy Mini Kit (Qiagen Inc., Valencia, CA) and
analyzed using a Nanodrop spectrophotometer (Thermo
Fisher Scientific Inc., Wilmington, DE). Samples were
reverse transcribed using a SuperScript® VILO cDNA
synthesis kit (Life Technologies, Grand Island, NY). Real-
time PCR was performed using FastStart Universal SYBR
Green master mix (Roche Diagnostics GmbH, Mannheim,
Germany) based on the manufacturer’s protocol. Primers
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BMP signaling pathway gene expression analysis was
performed using a human TGFβ/BMP Signaling Pathway
RT2 Profiler PCR Array System (Qiagen Inc.) with the
provided RT2 First Strand Kit for cDNA synthesis, preloa-
ded primer sets in 96-well format, and RT2 SYBR Green/
ROX PCR Master mix, according to manufacturer’s pro-
tocol. PCR reactions were performed in Mastercycler® ep
realplex 2 (Eppendorf, Hauppauge, NY) real-time thermal
cycler.SMURF1 knockdown by lentivirus delivered shRNA system
Human SMURF1 short hairpin RNA (shRNA) plasmids
were purchased from Open Biosystems (Thermo Fisher
Scientific Inc.). Three different SMURF1 targeting and
silencing plasmids containing green fluorescence protein
(GFP) and puromycin resistant genes (V2LHS_229724,
V2LHS_203332, and V2LHS_363173) were supplied in
E. coli competent cells. The cultures were expanded and
the plasmids extracted using a QIAGEN Plasmid Midi
kit (Qiagen Inc.). Extracted plasmids were then packaged
into a Trans-Lentiviral™ GIPZ lentivirus packaging system
(Open Biosystems) and transfected into the TLA-HEK293T
producer cell line according to the manufacturer’s supplied
protocol. Viral particle supernatants were collected at 48
and 72 h post-transfection and clarified by centrifuga-
tion. Clarified supernatants were filtered through a sterile
0.45 μm low protein-binding filter and concentrated to 1/
100th of the original volume using Lenti-X Concentrator
reagent (Clontech Laboratories, Inc., Mountain View,
CA). Concentrated viral particles were used to transduce
cells in adherent monolayer culture at approximately 50%
confluency in 1 mL complete medium supplemented with
8 μg/mL polybrene in 6-well plates overnight. After over-
night incubation, viral particles were removed and the
medium changed to normal growth conditions. Cells
expressing either non-targeting random sequence shRNA
(shNeg) control vector or SMURF1 targeting shRNA
(shSMURF1) were monitored for GFP expression and fur-
ther grown in selective medium containing 2 μg/mL puro-
mycin for 72 h to eliminate non-transduced cells.Protein extraction
Total protein was extracted from approximately 1 × 106
cells by incubating in RIPA lysis buffer (150 nM sodium
chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate,
0.1% sodium dodecyl sulphate, 50 nM Tris, pH 8.0, 10%
glycerol) supplemented with fresh Halt™ protease and
phosphatase inhibitor cocktail (Thermo Fisher Scientific
Inc.) at 1:100 dilutions for 30 min on ice with periodic
vortexing. Protein lysate supernatant was collected by
centrifugation at 20,000 × g for 10 min at 4°C to re-
move insoluble materials, and the protein concentrationsdetermined using a BCA™ protein assay kit (Thermo
Fisher Scientific Inc.).
Immunoblotting analysis
Immunoblotting was performed based on standard tech-
niques as described previously [68]. Briefly, protein samples
were boiled in 1X sample buffer and loaded onto 4 – 15%
gradient SDS-polyacrylamide gel at 50 μg/well for electro-
phoresis, transferred to nitrocellulose membrane, and
blocked with 50% Odyssey® Blocking Buffer (LI-COR
Biosciences, Lincoln, NE) diluted in TBST (20 mM Tris–
HCl pH 7.4, 137 mM NaCl, 0.1% Tween-20). Rabbit anti-
SMURF1 primary polyclonal antibody (Cat# AB10005;
EMD Millipore, Billerica, MA) was added at a 1:300 dilu-
tion in blocking buffer and incubated for 1 h at room
temperature. Rabbit anti-phospho-SMAD1 (Ser463/465)/
SMAD5 (Ser463/465)/SMAD8 (Ser426/428) or pSMAD1/
5/8 (Cat# 9511; Cell Signaling Technology, Danvers, MA)
and rabbit anti-SMAD1 as a total SMAD protein control
(Cat# 6944; Cell Signaling Technology) were used at a
1:1000 dilution. Mouse anti-β-actin antibody (1:1000 dilu-
tion) was used as loading control. The membrane was
washed three times with TBST, followed by incubation
with LI-COR IRDye 800CW (780 nm) donkey anti-rabbit
and IRDye 680RD (680 nm) donkey anti-mouse infra-
red fluorescence dye conjugated secondary antibodies
(LI-COR Biosciences) at a 1:10,000 dilution for 10 –
15 min at room temperature using the SNAP i.d. Western
Blotting System (EMD Millipore). After washing to re-
move excess secondary antibodies and Tween-20, the
membranes were scanned and documented using an
Odyssey infrared imaging system (LI-COR Biosciences) at
680 nm and 780 nm emission wavelengths.
Immunostaining and flow cytometry
Cell surface protein immunostaining was performed on
single-cell suspensions of live cells. Approximately 1 × 106
cells were incubated in immunostaining buffer (PBS con-
taining 2% FBS and 2 mM EDTA) for 10 min on ice
followed by incubation with the fluorescence conjugated
primary antibody on ice, for 30 min, and in the dark. APC
conjugated rat anti-human CD44 monoclonal antibody
IgG2bκ was used as described above at a 1:100 dilution to
detect CD44-positive cells. An APC conjugated rat non-
specific IgG2b isotype was used as a negative staining con-
trol. For co-staining with mouse monoclonal antibody to
detect intracellular SMURF1 protein, cells stained with
CD44-APC antibody were fixed in 10% phosphate
buffered formalin for 30 min on ice, permeabilized with
ice-cold 100% methanol for 30 min on ice or overnight
at 4°C, washed three times with staining buffer, and in-
cubated with fluorescently labeled mouse anti-human
SMURF1 monoclonal antibody (Sigma-Aldrich, Saint
Louis, MO) at 1 μg per 1 × 106 cells in PBS plus 1% BSA
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with Zenon® Pacific Blue fluorochrome for mouse IgG2a
(Life Technologies). Mouse non-specific IgG2a isotype
was labeled similarly and used as a negative staining
control. The cells were washed, resuspended in staining
buffer, and analyzed using a BD LSR II flow cytometer
(BD Biosciences).
Adipogenesis differentiation assay with Oil Red O staining
Adipogenesis assays were carried out using a StemPro®
Adipogenesis Differentiation kit (Life Technologies).
Monolayer and sphere cells were cultured overnight
in complete medium before switching to differentiation
medium. Complete medium and sphere cell culture me-
dium were used as negative controls for the monolayer
and sphere cells, respectively. Cells were grown in differ-
entiation or control medium for 7–14 days, with medium
change every three days. To visualize intracellular microli-
pid droplets, growth media were carefully aspirated and
cells were fixed in 4% paraformaldehyde for 30 – 40 min
at room temperature. Following three washes with PBS
and twice with water, Oil Red O solution (EMD Millipore)
was added to cover the cells and incubated at room
temperature for 50 min. Cells were then washed three
times with water, visualized under light microscopy,
and imaged.
Anchorage-independent colony formation
Cells (~5,000-10,000 per well) were grown as single-cell
suspensions in complete medium containing 20% FBS
and 50% Matrigel™ matrix on Ultra Low Cluster 96-well
plates (Corning, Inc.). Embedded cells were incubated in
37°C, 5% CO2 overnight to allow matrix polymerization
before topping off each well with 200 μL of complete
medium. Cells were fed every seven days for a total of
21 days to allow colonies to form. Colonies were visualized
by light microscopy using the lowest (4X) objective.
Cytotoxicity, cell viability, and cisplatin resistance
Cellular cytotoxicity assays were performed in tissue-
culture treated 96-well plates. Cells were seeded at 5,000 –
10,000 cells per well, overnight. Serial dilutions of cisplatin
(0 to 10 μM) were added to the cells and incubated for
72 h. Cell viability following cisplatin treatment was de-
termined by CellTiter 96® MTS assay (Promega Corp.,
Madison, WI). Cells were incubated with MTS solution
for 3 h at 37°C, 5% CO2, and the absorbance was measured
at 490 nm. Percent viability was calculated relative to
untreated control.
Statistics
Statistical analysis was performed using unpaired two-
tailed Student’s t-test with equal variance. Comparative
analysis with p-value < 0.05 was considered significant.Additional files
Additional file 1: Figure S1. Representative flow cytometry analysis of
CD44 surface protein expression in (A) TR146, (B) SCC-58, and (C)
UMSCC-17B monolayer (top) and sphere (bottom) cells as summarized in
Figure 1C. Isotype controls are shown on the left in each panel.
Additional file 2: Figure S2. Sphere cells are more resistant to cisplatin
than monolayer cells. Representative results from the SCC-58 and TR146
cell lines are shown. Cells were treated with cisplatin for 72 h and ratios
of viable cells were measured by an MTS assay. Data are shown as mean
± SD from at least three independent experiments.
Additional file 3: Figure S3. BMP ligand expression and secretion by
sphere cells. (A) BMP2, 4, and 7 expression in sphere cells relative to
monolayer cultures by qRT-PCR, shown as a representative of two
repeats. (B) BMP2 secretion was higher in sphere cell cultures compared
to their monolayer counterparts. Cell culture supernatants were collected
at day 3 from the monolayer cells and at days 3, 7, and 14 from the
sphere cells with a fresh medium change one day prior to sampling. The
level of extracellular BMP2 production was measured using an ELISA and
protein concentrations were normalized to the level of viable cells
present based on MTS absorbance values. Data are presented as the
concentration of BMP2 per MTS absorbance value, mean ± SD, performed
in duplicate.
Additional file 4: Figure S4. Representative flow cytometry analysis of
SDCs double-stained with CD44 cell surface and intracellular SMURF1
proteins. The data shown are representative of at least three independent
experiments.
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